Add Company
Join Now

Cyclo Therapeutics Revenue and Competitors

License our Company Data API

Location

#2718

Growjo Ranking

Pharma

Industry
Embed

Estimated Revenue & Valuation

  • Cyclo Therapeutics's estimated annual revenue is currently $2.1M per year.(i)
  • Cyclo Therapeutics's estimated revenue per employee is $100,500

Employee Data

  • Cyclo Therapeutics has 21 Employees.(i)
  • Cyclo Therapeutics grew their employee count by 5% last year.

Cyclo Therapeutics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$26.5M132N/AN/AN/A
#2
$10.1M5014%N/AN/A
#3
$282.6M1406N/AN/AN/A
#4
$13.9M6944%N/AN/A
#5
$11.3M564%N/AN/A
#6
$11.5M57-7%N/AN/A
#7
$211.7M10724%N/AN/A
#8
$24.1M1205%N/AN/A
#9
$7.8M39-2%N/AN/A
#10
$12.9M64-2%N/AN/A
Add Company

What Is Cyclo Therapeutics?

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is conducting a Phase 2b clinical trial using Trappsol® Cyclo™ intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.

keywords:N/A

N/A

Total Funding

21

Number of Employees

$2.1M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4M21-5%N/A
#2
$4M21-25%N/A
#3
N/A210%N/A
#4
$4.7M22-4%N/A
#5
N/A2229%N/A